Biocon starts clinical study to evaluate efficacy of Itolizumab
This is a phase-II randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Equillium
Biocon and Equillium expand exclusive licensing agreement for Itolizumab to include Australia and…
Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the US and…